TD Cowen changed its rating from “Buy” to “Hold,” a less favorable view. Its $23.50 price target matches the pending deal’s cash offer, so the note reports no new change to Surgery Partners’ business or deal terms.
The target matches the cash amount in the pending deal, so the note points back to terms already announced. The rating cut is a negative view, but the story reports no change to the deal or Surgery Partners’ business.
Follow Surgery Partners, Inc. (SGRY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SGRY